New Post-Hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia

Takeda Pharmaceuticals International and Sunovion Pharmaceuticals has announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA).

Download to find out more.

More About This Company